轨道动脉切除术对复杂的冠状动脉修饰的作用:它已经被掩盖了吗?
Natasha Khullar1, Trisha Singh1, Peter O'Kane1
1Dorset Heart Centre, Royal Bournemouth Hospital, Castle Lane East, Bournemouth BH7 7DW, UK.
Journal of personalized medicine
|September 26, 2025
概括
严重的冠状动脉化在穿皮冠状动脉干预期间带来了挑战. 轨道切除术在改善病变准备和支架部署方面显示出有前途,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 严重的冠状动脉化 (CAC) 在接受皮肤冠状动脉干预 (PCI) 的患者中很普遍.
- CAC导致血管刚性,使器械输送和支架扩张复杂化.
- 化病变增加并发症和心脏不良事件的风险,影响临床结果.
研究的目的:
- 审查轨道切除术 (OA) 在治疗结石化冠状动脉病变中的作用.
- 评估OA对PCI的安全性和有效性.
- 讨论OA在干预心脏病学中的未来定位.
主要方法:
- 对严重冠状动脉化的轨道切除术的当前文献的综述.
- 对OA的安全性和有效性进行现有临床证据的评估.
- 讨论OA的行动机制及其对PCI的影响.
主要成果:
- 轨道切除术 (OA) 是一种专门用于严重CAC的修饰技术.
- OA提供了一种独特的双重作用机制,有可能增强损伤的准备.
- 有证据表明,OA可以促进化病变中的最佳支架部署.
结论:
- 轨道切除术是管理复杂的结石化冠状动脉病变的宝贵工具.
- 在改善PCI结果方面,OA证明了安全性和有效性.
- 个性化,病变特定的方法对于优化PCI与OA至关重要.
相关概念视频
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
395
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
395
Coronary Artery Disease IV: Preventive Measures
590
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
590
Coronary Artery Disease II: Pathophysiology
374
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
374
Peripheral Artery Disease III: Interprofessional Care
245
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
245


